Clinical Trial

Study Evaluating Neoadjuvant Immunotherapy Increasing CD8+ Cell Infiltration in Advance Gastric Adenocarcinoma

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated March 8, 2022 (before its estimated March 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
Focusing on the clinical question of whether patients with advanced gastric cancer can benefit from immunotherapy, this project intends to detect the degree of CD8+ tumor-infiltrating lymphocyte infiltration in patients with advanced gastric cancer before and after receiving neoadjuvant combined immunotherapy and neoadjuvant therapy alone. To explore the evolving nature of tumor immune response before and after neoadjuvant therapy for gastric cancer, and quantitatively present it through chemical immunohistochemical techniques to achieve a more accurate diagnosis and treatment and improve the long-term efficacy of patients.
Trial Details
NCT Number NCT05270824
Lead Sponsor Fujian Medical University
Conditions Advanced Gastric Carcinoma, CD8+ Tumor Infiltrating Lymphocytes, Neoadjuvant Immunotherapy
Enrollment 120 participants
Start Date 2022-03-01
Primary Completion 2024-03-01 (estimated)
Study Completion 2027-03-01 (estimated)
Updated on ClinicalTrials.gov 2022-03-08